www.lesswrong.com/posts/QAB3BEDRziBerNAih/whack-a-mole-is-not-a-winnable-game
2 corrections found
as you can see by looking through the law, every scheduled chemical compound is specifically named.
The Controlled Substances Act’s schedules are not limited to individually named molecules; they also include broader class/structural definitions (e.g., “Tetrahydrocannabinols” covers synthetic equivalents/derivatives/isomers).
Full reasoning
The post claims that “every scheduled chemical compound is specifically named.” That is contradicted by the text of the federal schedules themselves.
For example, 21 CFR § 1308.11 (Schedule I) includes an entry for “Tetrahydrocannabinols” that is not a list of individually named molecules; it describes a broader set including “synthetic equivalents,” “derivatives,” and “isomers with similar chemical structure and pharmacological activity” to those found in the cannabis plant. That is a structural/class-style definition rather than “specifically named” compounds.
Because at least some scheduled substances are controlled by broad structural/class language, the statement that every scheduled chemical compound is “specifically named” is incorrect.
1 source
- 21 CFR § 1308.11 - Schedule I (e-CFR) | Cornell LII
Entry “(31) Tetrahydrocannabinols … (i) Meaning … synthetic equivalents … and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity …” (i.e., not limited to individually named molecules).
In other words, a compound is only a schedule-1 drug if that specific arrangement of atoms is regulated by the DEA. Slap a fluorine atom onto any of them, and it’s a whole new molecule, meaning it has to go through the entire regulatory process again.
U.S. law can treat unscheduled “analogues” as Schedule I (for federal law) when intended for human consumption, so new variants don’t necessarily need to be individually scheduled to be controlled/prosecuted.
Full reasoning
The post claims that a molecule is only Schedule I if that exact molecule is scheduled, and that altering it (e.g., adding fluorine) forces regulators to “go through the entire regulatory process again.” That is contradicted by the Federal Analog Act (codified at 21 U.S.C. § 813), which provides that a “controlled substance analogue” shall, if intended for human consumption, be treated as a Schedule I controlled substance for purposes of federal law.
Additionally, the DEA explicitly cautions that schedule lists are not comprehensive and that a substance “need not be listed as a controlled substance to be treated as a scheduled substance for criminal prosecution,” and notes that substances may be regulated as controlled substance analogues.
So while novel chemical modifications can create enforcement and proof challenges, it is not true that a variant necessarily must be newly scheduled via the full scheduling process before it can be treated as Schedule I under federal law.
2 sources
- 21 U.S. Code § 813 - Treatment of controlled substance analogues | Cornell LII
“A controlled substance analogue shall, to the extent intended for human consumption, be treated, for the purposes of any Federal law as a controlled substance in schedule I.”
- DEA Diversion Control Division | Controlled Substance Schedules
DEA notes the lists “are not comprehensive… a substance need not be listed… to be treated as a scheduled substance for criminal prosecution,” and that a substance may be regulated as a controlled substance analogue (citing 21 U.S.C. § 813).